Chemistry between ChemBridge and AstraZeneca
ChemBridge Corporation, of San Diego, US, has formed a multi-year research collaboration in discovery chemistry with AstraZeneca.
ChemBridge Corporation, of San Diego, US, has formed a multi-year research collaboration in discovery chemistry with AstraZeneca.
The new alliance follows the previous collaboration between ChemBridge and AstraZeneca that was established in 2006 and successfully completed earlier this year ahead of schedule. With the new agreement scientists from ChemBridge and AstraZeneca will design and develop a new generation of highly advanced, research-intensive small molecule libraries that further enhance AstraZeneca's global drug discovery effort. Details and financial terms were not disclosed.
Eugene Vaisberg, chairman and ceo of ChemBridge Corporation and ChemBridge Research Laboratories (CRL) said: "This major new deal, which is focused on the most challenging custom compound libraries, is further proof of ChemBridge's capabilities to succeed in the increasingly competitive global discovery chemistry outsourcing market by targeting its high-end segment and leveraging the skills, expertise and experience of ChemBridge's scientists."